MY208497A - Heterotandem bicyclic peptide complex - Google Patents

Heterotandem bicyclic peptide complex

Info

Publication number
MY208497A
MY208497A MYPI2022000296A MYPI2022000296A MY208497A MY 208497 A MY208497 A MY 208497A MY PI2022000296 A MYPI2022000296 A MY PI2022000296A MY PI2022000296 A MYPI2022000296 A MY PI2022000296A MY 208497 A MY208497 A MY 208497A
Authority
MY
Malaysia
Prior art keywords
peptide complex
bicyclic peptide
heterotandem bicyclic
heterotandem
relates
Prior art date
Application number
MYPI2022000296A
Other languages
English (en)
Inventor
Kevin Mcdonnell
Punit Upadhyaya
Johanna Lahdenranta
Gemma Mudd
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MY208497A publication Critical patent/MY208497A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MYPI2022000296A 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complex MY208497A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962880191P 2019-07-30 2019-07-30
US201962910088P 2019-10-03 2019-10-03
US201962931442P 2019-11-06 2019-11-06
US202063022667P 2020-05-11 2020-05-11
US202063024715P 2020-05-14 2020-05-14
PCT/GB2020/051828 WO2021019244A1 (en) 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complex

Publications (1)

Publication Number Publication Date
MY208497A true MY208497A (en) 2025-05-13

Family

ID=71948620

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2022000306A MY208496A (en) 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complex
MYPI2022000296A MY208497A (en) 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complex

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MYPI2022000306A MY208496A (en) 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complex

Country Status (15)

Country Link
US (7) US11312749B2 (enExample)
EP (4) EP4003527A1 (enExample)
JP (5) JP7579840B2 (enExample)
KR (3) KR20220051345A (enExample)
CN (4) CN114502598A (enExample)
AU (3) AU2020323739B2 (enExample)
BR (3) BR112022001520A2 (enExample)
CA (3) CA3148039A1 (enExample)
IL (3) IL290093A (enExample)
MX (3) MX2022001288A (enExample)
MY (2) MY208496A (enExample)
PH (2) PH12022550173A1 (enExample)
SA (2) SA522431586B1 (enExample)
TW (2) TWI862640B (enExample)
WO (4) WO2021019245A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054526T2 (hu) 2014-10-29 2021-09-28 Bicyclerd Ltd MT1-MMP-ra specifikus biciklusos peptid ligandumok
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
EP3661948B1 (en) 2017-08-04 2022-06-01 BicycleTx Limited Bicyclic peptide ligands specific for cd137
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
SG11202007678QA (en) 2018-02-23 2020-09-29 Bicycletx Ltd Multimeric bicyclic peptide ligands
JP7551500B2 (ja) 2018-04-04 2024-09-17 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
CN113811541A (zh) 2019-05-09 2021-12-17 拜斯科技术开发有限公司 Ox40特异性的双环肽配体
TWI862640B (zh) * 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
HUE072242T2 (hu) * 2019-10-03 2025-11-28 Bicycletx Ltd Heterotandem biciklusos peptidkomplexek
MX2023001588A (es) 2020-08-17 2023-05-03 Bicycletx Ltd Conjugados biciclo específicos para nectina-4 y usos de estos.
US20250186539A2 (en) * 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
KR20240042656A (ko) * 2021-08-17 2024-04-02 메드샤인 디스커버리 아이엔씨. 신규구조를 갖는 폴리펩타이드 접합체 약물 및 그 응용
WO2023051396A1 (zh) * 2021-09-29 2023-04-06 南京明德新药研发有限公司 三环多肽偶联药物及其应用
MX2024005855A (es) * 2021-11-16 2024-05-28 Bicycletx Ltd Procedimientos para tratar el cancer.
CN116768978A (zh) * 2022-03-11 2023-09-19 上海智肽生物科技有限公司 Nectin-4靶向肽化合物及其药物偶联物
WO2024229427A1 (en) * 2023-05-04 2024-11-07 Tambo, Inc. Tetrazine-based targeting agents for in vivo delivery of a payload
WO2025191096A1 (en) * 2024-03-14 2025-09-18 Bicycletx Limited Bicyclic peptide
WO2025248261A1 (en) 2024-05-31 2025-12-04 Bicycletx Limited Method for identifying patients

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642514A (en) 1946-08-10 1953-06-16 American Cyanamid Co Ion exchange process with magnetic ion exchange resins
GB1239978A (en) 1968-07-15 1971-07-21 Permutt Company Ltd Ion-exchange processes
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
CA2264610A1 (en) 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
ATE389030T1 (de) 1998-09-24 2008-03-15 Univ Indiana Res & Tech Corp Wasserlösliche lumineszente quantum-dots sowie deren biokonjugate
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
SK287188B6 (sk) 1999-12-10 2010-02-08 Pfizer Products Inc. Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom
CA2445395C (en) 2001-04-27 2010-03-30 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent comprising the same as effective component
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1487972T3 (en) 2002-02-21 2015-10-19 Inst Virology MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
BRPI0313733A8 (pt) 2002-08-14 2016-08-16 Atugen Ag Uso da proteína n beta cinase
AU2003286411A1 (en) 2002-12-12 2004-06-30 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
US7151047B2 (en) 2004-04-28 2006-12-19 Warren Chan Stable, water-soluble quantum dot, method of preparation and conjugates thereof
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
SI1844337T1 (sl) 2005-01-24 2013-11-29 Pepscan Systems B.V. Povezovalne spojine, imunogene spojine in peptidomimetiki
PL1866328T3 (pl) 2005-03-22 2011-05-31 Rohto Pharma Peptydy zwiększające wytwarzanie kolagenu lub kwasu hialuronowego
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
WO2007030642A2 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
NZ608667A (en) 2005-10-07 2014-08-29 Exelixis Inc N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
NZ572812A (en) 2006-04-26 2010-09-30 Hoffmann La Roche THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
US7666392B2 (en) 2006-09-15 2010-02-23 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
ES2616789T3 (es) 2006-09-22 2017-06-14 Pharmacyclics, Inc. Inhibidores de tirosina cinasa de Bruton
CN101232326B (zh) 2007-01-22 2012-01-11 中兴通讯股份有限公司 用于无源光网络系统的动态带宽分配装置及其实现方法
PL2152701T3 (pl) 2007-03-12 2016-10-31 Związki fenyloaminopirymidyny i ich zastosowania
WO2008134761A2 (en) 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CN101918844A (zh) 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗
CN101497878B (zh) 2008-01-30 2012-11-07 房学迅 特异性高效亲和膜ⅰ型基质金属蛋白酶(mt1-mmp)的多肽、蛋白及其应用
WO2009098450A2 (en) * 2008-02-05 2009-08-13 Medical Research Council Methods and compositions
AU2009219682B2 (en) 2008-02-27 2015-06-18 Yeda Research & Development Co. Ltd RGD-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors
NZ587928A (en) 2008-03-11 2012-08-31 Incyte Corp Azetidine and cyclobutane derivatives as jak inhibitors
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
FR2932189A1 (fr) 2008-06-10 2009-12-11 Commissariat Energie Atomique Biopuces pour la detection de l'activite enzymatique d'une enzyme protease
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
US20120183847A1 (en) 2009-05-19 2012-07-19 Aic Blab Composite current collector and methods therefor
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US9073974B2 (en) 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
JP2013518807A (ja) 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
US20130072598A1 (en) 2011-03-18 2013-03-21 Board Of Regents Of The University Of Nebraska Thermoplastics from Distillers Dried Grains and Feathers
PL2764140T3 (pl) 2011-10-07 2018-04-30 Bicyclerd Limited Modulacja specyficzności polipeptydów ustrukturyzowanych
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
EP2898085B1 (en) 2012-09-24 2019-01-23 MedImmune Limited Cell lines
WO2014063012A1 (en) 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
US9790286B2 (en) * 2013-01-02 2017-10-17 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis
CA2902432A1 (en) 2013-03-12 2014-10-09 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
US20140274759A1 (en) 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
EP2976362B1 (en) 2013-03-19 2019-10-23 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
US9868767B2 (en) 2013-05-23 2018-01-16 Ohio State Innovation Foundation Chemical synthesis and screening of bicyclic peptide libraries
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
SG11201602889TA (en) 2013-10-28 2016-05-30 Bicycle Therapeutics Ltd Novel polypeptides
WO2015116904A1 (en) 2014-02-03 2015-08-06 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
JP6875129B2 (ja) 2014-05-08 2021-05-19 ノボダイアックス， インコーポレイテッド 直接的な免疫組織化学アッセイ
PL3149025T3 (pl) 2014-05-21 2019-11-29 Entrada Therapeutics Inc Peptydy penetrujące komórkę i sposoby ich wytwarzania i stosowania
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
CA2963226A1 (en) 2014-09-30 2016-04-07 Polyphor Ag Beta-hairpin peptidomimetics
EP3209329A4 (en) 2014-10-24 2018-03-28 Research Corporation Technologies, Inc. Small antibody-like polypeptides that bind to epha2 receptor
HUE054526T2 (hu) 2014-10-29 2021-09-28 Bicyclerd Ltd MT1-MMP-ra specifikus biciklusos peptid ligandumok
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
MX2017007218A (es) 2014-12-04 2018-02-21 Celgene Corp Conjugados de biomoleculas.
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
CN107529836A (zh) 2015-04-22 2018-01-02 三井化学株式会社 具有关节用支撑体部的衣物、及膝用支撑体
WO2016171242A1 (ja) 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
AU2016256226A1 (en) 2015-04-28 2017-11-23 Ecole polytechnique fédérale de Lausanne (EPFL) Novel inhibitors of the enzyme activated factor XII (FXIIa)
HK1253005A1 (zh) 2015-05-06 2019-06-06 Janssen Biotech, Inc. 前列腺特异性膜抗原结合iii型纤连蛋白结构域
MX390894B (es) * 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
EP3115066A1 (en) 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
US9963495B2 (en) 2015-10-27 2018-05-08 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor and prostate specific membrane antigen
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
GB201600911D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
US10765625B2 (en) 2016-03-15 2020-09-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
CN108883199A (zh) 2016-03-16 2018-11-23 梅里麦克制药股份有限公司 肝配蛋白受体a2(epha2)的纳米脂质体靶向和相关诊断
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
MY197235A (en) * 2016-04-20 2023-06-07 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
ES2910365T3 (es) * 2016-04-22 2022-05-12 Alligator Bioscience Ab Nuevos polipéptidos biespecíficos contra CD137
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
AU2017271601A1 (en) 2016-05-27 2018-12-13 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
US10441663B2 (en) 2016-11-27 2019-10-15 Bicyclerd Limited Methods for treating cancer
WO2018115204A1 (en) 2016-12-23 2018-06-28 Bicycletx Limited Peptide ligands for binding to mt1-mmp
US11730819B2 (en) 2016-12-23 2023-08-22 Bicycletx Limited Peptide derivatives having novel linkage structures
ES2985986T3 (es) 2017-01-06 2024-11-08 Bicyclerd Ltd Conjugado biciclo para tratar el cáncer
CA3053803A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
WO2018222987A1 (en) 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
EP3661948B1 (en) 2017-08-04 2022-06-01 BicycleTx Limited Bicyclic peptide ligands specific for cd137
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) * 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
US11572370B2 (en) 2018-01-08 2023-02-07 Biohaven Therapeutics Ltd. CD16A binding agents and uses thereof
SG11202007678QA (en) 2018-02-23 2020-09-29 Bicycletx Ltd Multimeric bicyclic peptide ligands
JP7551500B2 (ja) 2018-04-04 2024-09-17 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体
CN112384534A (zh) 2018-05-21 2021-02-19 指南针制药有限责任公司 用于增强nk细胞对靶细胞的杀死的组合物和方法
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810329D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810325D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
US20200129630A1 (en) 2018-10-30 2020-04-30 Bicyclerd Limited Methods for treating cancer
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020120984A1 (en) 2018-12-13 2020-06-18 Bicycletx Limited Bicyclic peptide ligands specific for mt1-mmp
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
CN113260420A (zh) 2018-12-21 2021-08-13 拜斯科阿迪有限公司 Pd-l1特异性的双环肽配体
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
US10882987B2 (en) 2019-01-09 2021-01-05 Nova Chemicals (International) S.A. Ethylene interpolymer products having intermediate branching
GB201900525D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
GB201900527D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
EP3935069A1 (en) 2019-03-04 2022-01-12 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
EP3946462A1 (en) 2019-04-02 2022-02-09 BicycleTX Limited Bicycle toxin conjugates and uses thereof
CN113811541A (zh) 2019-05-09 2021-12-17 拜斯科技术开发有限公司 Ox40特异性的双环肽配体
TWI869398B (zh) 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4013501A1 (en) 2019-08-13 2022-06-22 BicycleTX Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
HUE072242T2 (hu) 2019-10-03 2025-11-28 Bicycletx Ltd Heterotandem biciklusos peptidkomplexek
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
US20220387611A1 (en) 2019-10-16 2022-12-08 Bicyclerd Limited Methods for treating cancer
US20230025916A1 (en) 2019-11-27 2023-01-26 Bicycle TX Limited BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF
IT202000001231A1 (it) 2020-01-22 2021-07-22 Celery S R L Nuovi ceppi di batteri lattici, composizione alimentare che li comprende, preparazione di tale composizione
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
IL298382A (en) 2020-05-20 2023-01-01 Bicycletx Ltd Nectin-4-specific bicyclic peptide ligands and their uses
EP4165414A1 (en) 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
US20220031858A1 (en) 2020-08-03 2022-02-03 Bicycle TX Limited Novel linkers
MX2023001588A (es) 2020-08-17 2023-05-03 Bicycletx Ltd Conjugados biciclo específicos para nectina-4 y usos de estos.
DK4274838T3 (da) 2021-01-08 2024-10-21 Bicycletx Ltd Bicykliske peptidligander, der er specifikke for NK-celler
US20240197897A1 (en) 2021-01-08 2024-06-20 Bicycle TX Limited Heterotandem bicyclic peptide complexes
US20240083945A1 (en) 2021-01-08 2024-03-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
JP2024533157A (ja) 2021-09-03 2024-09-12 バイスクルテクス・リミテッド 二環式毒素複合体およびその中間体の合成
MX2024005855A (es) 2021-11-16 2024-05-28 Bicycletx Ltd Procedimientos para tratar el cancer.

Also Published As

Publication number Publication date
WO2021019244A1 (en) 2021-02-04
MX2022001290A (es) 2022-02-22
JP7620002B2 (ja) 2025-01-22
IL290093A (en) 2022-03-01
JP2022544058A (ja) 2022-10-17
KR20220051345A (ko) 2022-04-26
CN114555626A (zh) 2022-05-27
WO2021019245A1 (en) 2021-02-04
JP2022542386A (ja) 2022-10-03
US11312749B2 (en) 2022-04-26
EP4003527A1 (en) 2022-06-01
JP2025122030A (ja) 2025-08-20
BR112022001520A2 (pt) 2022-06-21
US20230129258A1 (en) 2023-04-27
BR112022001532A2 (pt) 2022-06-07
WO2021019243A1 (en) 2021-02-04
US20220257784A1 (en) 2022-08-18
US20210040154A1 (en) 2021-02-11
EP4003530A1 (en) 2022-06-01
AU2020322193A1 (en) 2022-03-17
TW202118770A (zh) 2021-05-16
MY208496A (en) 2025-05-13
US12435107B2 (en) 2025-10-07
BR112022001521A2 (pt) 2022-07-12
AU2020323739A1 (en) 2022-03-17
CA3148033A1 (en) 2021-02-04
US11970553B2 (en) 2024-04-30
TWI862640B (zh) 2024-11-21
JP2022542291A (ja) 2022-09-30
US20220227811A1 (en) 2022-07-21
CN114502598A (zh) 2022-05-13
IL290089A (en) 2022-03-01
CN114521197B (zh) 2025-04-11
CN114555626B (zh) 2025-04-08
US20210069287A1 (en) 2021-03-11
US20240336656A1 (en) 2024-10-10
SA522431587B1 (ar) 2024-04-24
AU2020319704B2 (en) 2025-08-14
AU2020323739B2 (en) 2025-11-06
MX2022001288A (es) 2022-02-22
JP7579840B2 (ja) 2024-11-08
TW202110485A (zh) 2021-03-16
JP7682852B2 (ja) 2025-05-26
EP4003528A1 (en) 2022-06-01
EP4003529A1 (en) 2022-06-01
US11306123B2 (en) 2022-04-19
IL290090A (en) 2022-03-01
CN114521197A (zh) 2022-05-20
TWI860386B (zh) 2024-11-01
JP2022542286A (ja) 2022-09-30
CA3148039A1 (en) 2021-02-04
MX2022001273A (es) 2022-02-22
AU2020319704A1 (en) 2022-03-17
CA3147570A1 (en) 2021-02-04
KR20220049529A (ko) 2022-04-21
SA522431586B1 (ar) 2024-04-24
PH12022550171A1 (en) 2023-05-15
US20220242911A1 (en) 2022-08-04
PH12022550173A1 (en) 2022-11-14
JP7704732B2 (ja) 2025-07-08
KR20220054309A (ko) 2022-05-02
WO2021019246A1 (en) 2021-02-04
CN114341190A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
MY208497A (en) Heterotandem bicyclic peptide complex
EP4464721A3 (en) Heterotandem bicyclic peptide complexes
MX2020010444A (es) Complejos de péptidos bicíclicos en heterotándem.
MX2023008168A (es) Complejos peptidicos biciclicos heterotandem.
PH12020552179A1 (en) Bicyclic peptide ligands specific for nectin-4
PH12019500270A1 (en) Combination therapy for cancer
MX2021013669A (es) Ligandos peptidicos biciclicos especificos para ox40.
PH12018500520A1 (en) Cd3 binding polypeptides
PH12019550233A1 (en) A novel anti-c-met antibody and use thereof
MX2009008656A (es) Anticuerpos contra erbb3 y usos de los mismos.
NZ731185A (en) Bicyclic peptide ligands specific for mt1-mmp
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
NZ750426A (en) Modified t lymphocytes having improved specificity
MX366223B (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2018014863A (es) Régimen de dosificación para proteína de fusión de tcr especifico de gp100 - scfv anti - cd3.
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019183093A8 (en) High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
WO2019100052A3 (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
MX2024004429A (es) Regimenes de dosificacion del anticuerpo anti-ctla-4.
AR119512A1 (es) Complejo de péptidos bicíclicos hetero-tándem
MX2022008061A (es) Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento del miembro 8 de la superfamilia de inmunoglobulina(igsf8).
PH12021551959A1 (en) Combinations of binding moieties that bind egfr, her2 and her3.
MX2019013019A (es) USO DE 3,16-DIACETADO DE 26-AZIDO-22-OXOCOLEST-5-3ß, 16ß-DIILO COMO AGENTE ANTICANCERIGENO.